bioAffinity Technologies, Inc. Common Stock
BIAF XNASAbout bioAffinity Technologies, Inc. Common Stock
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| TTM 2025 | $6.16M | $-14,909,754 | $-8.66 |
| FY 2025 | $6.16M | $-14,909,754 | $-8.66 |
| Q3 2025 | $1.45M | $-5,051,084 | $-4.74 |
| Q2 2025 | $1.27M | $-4,060,787 | $-0.17 |
TickerDaily Coverage
Get BIAF Alerts
Stay ahead with breaking news, price alerts, and expert analysis on bioAffinity Technologies, Inc. Common Stock.